ReviewCurrent topics in medicinal chemistry2025
Rheumatoid Arthritis: Pathogenesis, Therapeutic Strategies, Advances, and Structural Activity Relationships of Synthesized Agents.
Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy.Gut microbes · 2026Review
- From Static to Dynamic: The Convergence of Nanomaterials and 3D/4D Bioprinting for Adaptive Wearable Sports Biosensors.Biosensors · 2026Review
- A Study on the Treatment of Rheumatoid Arthritis Using a Novel GelMA-HAMA Dual-Network Hydrogel Microneedle Loaded with MTX-NCs in Combination with Adalimumab.International journal of molecular sciences · 2026Article
- The emerging role of histone acetylation in rheumatic diseases: unraveling mechanisms and therapeutic prospects.Frontiers in immunology · 2026Review
- Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis, characterized by chronic inflammation of the synovial membrane. Current therapeutic options have advanced RA management significantly, yet limitations like adverse effects and treatment resistance underscore the need for novel therapeutic agents. Recent advancements have introduced promising candidates, including BTK inhibitors, JAK inhibitors, TLR4 inhibitors, COX-2 inhibitors, and LOX inhibitors, which target specific pathways implicated in RA pathogenesis. This manuscript provides a comprehensive overview of RA, emphasizing its pathophysiology, diagnostic approaches, and therapeutic strategies. Special attention is given to the structural-activity relationships (SAR) and mechanistic insights underlying emerging pharmacological interventions. Moreover, current challenges and future directions in RA drug discovery are critically examined, highlighting innovative wet-lab approaches to address unmet clinical needs.
Indexed as
Identifiers
40231515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.